期刊文献+

Herbal hepatotoxicity:Challenges and pitfalls of causality assessment methods 被引量:9

Herbal hepatotoxicity:Challenges and pitfalls of causality assessment methods
下载PDF
导出
摘要 The diagnosis of herbal hepatotoxicity or herb induced liver injury(HILI) represents a particular clinical and regulatory challenge with major pitfalls for the causality evaluation.At the day HILI is suspected in a patient,physicians should start assessing the quality of the used herbal product,optimizing the clinical data for completeness,and applying the Council for International Organizations of Medical Sciences(CIOMS) scale for initial causality assessment.This scale is structured,quantitative,liver specific,and validated for hepatotoxicity cases.Its items provide individual scores,which together yield causality levels of highly probable,probable,possible,unlikely,and excluded.After completion by additional information including raw data,this scale with all items should be reported to regulatory agencies and manufacturers for further evaluation.The CIOMS scale is preferred as tool for assessing causality in hepatotoxicity cases,compared to numerous other causality assessment methods,which are inferior on various grounds.Among these disputed methods are the Maria and Victorino scale,an insufficiently qualified,shortened version of the CIOMS scale,as well as various liver unspecific methods such as thead hoc causality approach,the Naranjo scale,the World Health Organization(WHO) method,and the Karch and Lasagna method.An expert panel is required for the Drug Induced Liver Injury Network method,the WHO method,and other approaches based on expert opinion,which provide retrospective analyses with a long delay and thereby prevent a timely assessment of the illness in question by the physician.In conclusion,HILI causality assessment is challenging and is best achieved by the liver specific CIOMS scale,avoiding pitfalls commonly observed with other approaches. The diagnosis of herbal hepatotoxicity or herb induced liver injury (HILI) represents a particular clinical and regulatory challenge with major pitfalls for the causality evaluation. At the day HILI is suspected in a patient, physicians should start assessing the quality of the used herbal product, optimizing the clinical data for completeness, and applying the Council for International Organizations of Medical Sciences (CIOMS) scale for initial causality assessment. This scale is structured, quantitative, liver specific, and validated for hepatotoxicity cases. Its items provide individual scores, which together yield causality levels of highly probable, probable, possible, unlikely, and excluded. After completion by additional information including raw data, this scale with all items should be reported to regulatory agencies and manufacturers for further evaluation. The CIOMS scale is preferred as tool for assessing causality in hepatotoxicity cases, compared to numerous other causality assessment methods, which are inferior on various grounds. Among these disputed methods are the Maria and Victorino scale, an insufficiently qualified, shortened version of the CIOMS scale, as well as various liver unspecific methods such as the ad hoc causality approach, the Naranjo scale, the World Health Organization (WHO) method, and the Karch and Lasagna method. An expert panel is required for the Drug Induced Liver Injury Network method, the WHO method, and other approaches based on expert opinion, which provide retrospective analyses with a long delay and thereby prevent a timely assessment of the illness in question by the physician. In conclusion, HILI causality assessment is challenging and is best achieved by the liver specific CIOMS scale, avoiding pitfalls commonly observed with other approaches.
出处 《World Journal of Gastroenterology》 SCIE CAS 2013年第19期2864-2882,共19页 世界胃肠病学杂志(英文版)
关键词 Herbal HEPATOTOXICITY Herb INDUCED LIVER INJURY Herbs DRUG HEPATOTOXICITY DRUG INDUCED LIVER INJURY CAUSALITY assessment Herbal hepatotoxicity Herb induced liver injury Herbs Drug hepatotoxicity Drug induced liver injury Causality assessment
  • 相关文献

参考文献3

二级参考文献26

  • 1WHO Traditional Medicines Strategy: 2002-2005. Geneva,World Health Organization, 2002 (document WHO/EDM/TRM/2002.1).
  • 2Good Manufacturing Practices for pharmaceutical products:main principles. In:WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report.Geneva, World Health Organization, 2003, Annex 4 (WHO Technical Report Series ,No. 908).
  • 3Good manufacturing practices:supplementary guidelines for manufacture of herbal medicinal products. In:WHO Expert Committee on Specifications for Pharmaceutical Preparations.Thirty-fourth report. Geneva, World Health Organization,1996, Annex 8 (WHO Technical Report Series, No. 863).(These guidelines are also included in Quality Assurance of Pharmaceuticals: A compendium of guidelines and related materials, Vol. 2: Good manufacturing practices and inspection. Geneva,World Health Organization, 1999. )
  • 4Quality control methods for medicinal plant materials. Geneva,World Health Organization, 1998.
  • 5Guide to good storage practices for pharmaceuticals. In:WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report. Geneva, World Health Organization, 2003, Annex 9 (WHO Technial Report Series,No. 908).
  • 6Good trade and distribution practices ( GTDP ) for pharmaceutical starting materials. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report. Geneva, World Health Organization,in press, Annex 2 (WHO Technical Report Series)
  • 7General guidelines for methodologies on research and evaluation of traditional medicine. Geneva, World Health Organization,2000(document WHO/EDM/TRM/2000.1)
  • 8Guidelines for the assessment of herbal medicines. In:WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fourth report. Geneva, World Health Organization, 1996 ,Annex 11 (WHO Technical Report Series,No. 863). (These guidelines are also included in Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials, Vol. 1. Geneva, World Health Organization, 1997. )
  • 9WHO monographs on selected medicinal plants,Vol. I. Geneva ,World Health Organization, 1999.
  • 10WHO monographs on selected medicinal plants, Vol. 2.Geneva, World Health Organization, 2002.

共引文献64

同被引文献152

引证文献9

二级引证文献166

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部